Herlinde D.
- Country
- Belgium
- Department
- General Medical Oncology
Research Overview
- Extension Study for Continued Treatment in Cancer Patients Using Atezolizumab, Tiragolumab, Ipatasertib, and Abiraterone or Drug Combination
- Phase 3 Study of Enfortumab Vedotin and Pembrolizumab Versus Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Cancer
- Efficacy Assessment of Induction Carboplatin, Paclitaxel, and Pembrolizumab in Locoregionally Advanced Penile Cancer: A Phase 2 Clinical Study
Data & Insights
Has run more than one trial at 83 of 221 partner sites.
Specializations
Urothelial Cancer Research
The investigator specializes in treating various forms of urothelial cancer, with particular emphasis on locally advanced and metastatic cases. Their research encompasses both traditional and innovative therapeutic approaches.
- Advanced Urothelial Carcinoma Treatment
- Metastatic Disease Management
- Muscle-Invasive Bladder Cancer
They focus on developing therapeutic strategies for patients with complex urological malignancies.
Immunotherapy Applications
The investigator explores immunotherapeutic approaches in urological oncology, particularly studying various combinations with checkpoint inhibitors and targeted therapies.
- Combination Immunotherapy
- Novel Immunological Agents
- Personalized Treatment Strategies
Their work integrates innovative immunological approaches with established treatment protocols.
Specialized Cancer Areas
The investigator's expertise extends to treating penile cancer and other rare urological malignancies, implementing multimodal treatment approaches.
- Locoregionally Advanced Disease
- Neoadjuvant Therapy
- Advanced Solid Tumors
Their research encompasses various therapeutic strategies for complex urological cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.